Impact of complications on long-term survival after resection of intrahepatic cholangiocarcinoma

Cancer

Volumn 121, Issue 16, 2015, Pages 2730-2739

  Spolverato, Gaya ^a   Yakoob, Mohammad Y ^a   Kim, Yuhree ^a   Alexandrescu, Sorin ^b   Marques, Hugo P ^c   Lamelas, Jorge ^c   Aldrighetti, Luca ^d   Gamblin, T Clark ^e   Maithel, Shishir K ^f   Pulitano, Carlo ^g   Bauer, Todd W ^h   Shen, Feng ⁱ   Poultsides, George A ^j   Marsh, J Wallis ^k   Pawlik, Timothy M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FUNDENI CLINICAL INSTITUTE   (Romania)

^c HOSPITAL CURRY CABRAL   (Portugal)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e MEDICAL COLLEGE OF WISCONSIN   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF SYDNEY   (Australia)

^h UNIVERSITY OF VIRGINIA   (United States)

ⁱ EASTERN HEPATOBILIARY SURGERY HOSPITAL   (China)

^j STANFORD UNIVERSITY   (United States)

^k UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

more..

Author keywords

complications; intrahepatic cholangiocarcinoma; recurrence; survival

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGE DISTRIBUTION; ARTICLE; BILE DUCT CARCINOMA; CANCER PROGNOSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; LIVER RESECTION; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SURVIVAL TIME; AGED; BILE DUCT NEOPLASMS; CHOLANGIOCARCINOMA; INTRAHEPATIC BILE DUCT; MIDDLE AGED; MORTALITY;

AGED; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; FEMALE; HUMANS; MALE; MIDDLE AGED; MORBIDITY; POSTOPERATIVE COMPLICATIONS;

EID: 84938737957     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29419     Document Type: Article

References (41)

1. El-Serag HB, Engels EA, Landgren O, et al., Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: a population-based study of U.S. veterans. Hepatology. 2009; 49: 116-123.
2. Endo I, Gonen M, Yopp AC, et al., Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008; 248: 84-96.
3. Malhi H, Gores GJ,. Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol. 2006; 45: 856-867.
4. Shaib YH, Davila JA, McGlynn K, El-Serag HB,. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol. 2004; 40: 472-477.
5. Welzel TM, McGlynn KA, Hsing AW, O'Brien TR, Pfeiffer RM,. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst. 2006; 98: 873-875.
6. Khan SA, Toledano MB, Taylor-Robinson SD,. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford). 2008; 10: 77-82.
7. Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM,. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis [published online ahead of print April 9, 2014]. JAMA Surg. doi: 10.1001/jamasurg.2013.5137.
8. de Jong MC, Nathan H, Sotiropoulos GC, et al., Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol. 2011; 29: 3140-3145.
9. Hyder O, Hatzaras I, Sotiropoulos GC, et al., Recurrence after operative management of intrahepatic cholangiocarcinoma. Surgery. 2013; 153: 811-818.
10. Hyder O, Marques H, Pulitano C, et al., A nomogram to predict long-term survival after resection for intrahepatic cholangiocarcinoma: an Eastern and Western experience. JAMA Surg. 2014; 149: 432-438.
11. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A,. AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010.
12. Beilin B, Bessler H, Mayburd E, et al., Effects of preemptive analgesia on pain and cytokine production in the postoperative period. Anesthesiology. 2003; 98: 151-155.
13. Wortel CH, van Deventer SJ, Aarden LA, et al., Interleukin-6 mediates host defense responses induced by abdominal surgery. Surgery. 1993; 114: 564-570.
14. Lundy J, Ford CM,. Surgery, trauma and immune suppression. Evolving the mechanism. Ann Surg. 1983; 197: 434-438.
15. Balkwill F, Mantovani A,. Inflammation and cancer: back to Virchow? Lancet. 2001; 357: 539-545.
16. Karpoff HM, Tung C, Ng B, Fong Y,. Interferon gamma protects against hepatic tumor growth in rats by increasing Kupffer cell tumoricidal activity. Hepatology. 1996; 24: 374-379.
17. Kooby DA, Stockman J, Ben-Porat L, et al., Influence of transfusions on perioperative and long-term outcome in patients following hepatic resection for colorectal metastases. Ann Surg. 2003; 237: 860-869; discussion 869-870.
18. Mavros MN, de Jong M, Dogeas E, Hyder O, Pawlik TM,. Impact of complications on long-term survival after resection of colorectal liver metastases. Br J Surg. 2013; 100: 711-718.
19. Couinaud C,. Liver anatomy: portal (and suprahepatic) or biliary segmentation. Dig Surg. 1999; 16: 459-467.
20. Mayo SC, Shore AD, Nathan H, et al., Refining the definition of perioperative mortality following hepatectomy using death within 90 days as the standard criterion. HPB (Oxford). 2011; 13: 473-482.
21. Dindo D, Demartines N, Clavien PA,. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004; 240: 205-213.
22. Wei AC, Tung-Ping Poon R, Fan ST, Wong J,. Risk factors for perioperative morbidity and mortality after extended hepatectomy for hepatocellular carcinoma. Br J Surg. 2003; 90: 33-41.
23. Spolverato G, Ejaz A, Hyder O, Kim Y, Pawlik TM,. Failure to rescue as a source of variation in hospital mortality after hepatic surgery. Br J Surg. 2014; 101: 836-846.
24. Virani S, Michaelson JS, Hutter MM, et al., Morbidity and mortality after liver resection: results of the patient safety in surgery study. J Am Coll Surg. 2007; 204: 1284-1292.
25. Tanaka K, Kumamoto T, Nojiri K, Matsuyama R, Takeda K, Endo I,. Impact of postoperative morbidity on long-term survival after resection for colorectal liver metastases [published online ahead of print September 28, 2010]. Ann Surg Oncol.
26. Spolverato G, Ejaz A, Kim Y, et al., Tumor size predicts vascular invasion and histologic grade among patients undergoing resection of intrahepatic cholangiocarcinoma. J Gastrointest Surg. 2014; 18: 1284-1291.
27. Laurent C, Sa Cunha A, Couderc P, Rullier E, Saric J,. Influence of postoperative morbidity on long-term survival following liver resection for colorectal metastases. Br J Surg. 2003; 90: 1131-1136.
28. Farid SG, Aldouri A, Morris-Stiff G, et al., Correlation between postoperative infective complications and long-term outcomes after hepatic resection for colorectal liver metastasis. Ann Surg. 2010; 251: 91-100.
29. Spolverato G, Kim Y, Alexandrescu S, et al., Is hepatic resection for large or multifocal intrahepatic cholangiocarcinoma justified? Results from a multi-institutional collaboration [published online ahead of print October 30, 2014]. Ann Surg Oncol.
30. Vigano L, Ferrero A, Lo Tesoriere R, Capussotti L,. Liver surgery for colorectal metastases: results after 10 years of follow-up. Long-term survivors, late recurrences, and prognostic role of morbidity. Ann Surg Oncol. 2008; 15: 2458-2464.
31. Ito H, Are C, Gonen M, et al., Effect of postoperative morbidity on long-term survival after hepatic resection for metastatic colorectal cancer. Ann Surg. 2008; 247: 994-1002.
32. Schiesser M, Chen JW, Maddern GJ, Padbury RT,. Perioperative morbidity affects long-term survival in patients following liver resection for colorectal metastases. J Gastrointest Surg. 2008; 12: 1054-1060.
33. Khuri SF, Henderson WG, DePalma RG, et al., Determinants of long-term survival after major surgery and the adverse effect of postoperative complications. Ann Surg. 2005; 242: 326-341; discussion 341-323.
34. Wong VK, Malik HZ, Hamady ZZ, et al., C-reactive protein as a predictor of prognosis following curative resection for colorectal liver metastases. Br J Cancer. 2007; 96: 222-225.
35. Colacchio TA, Yeager MP, Hildebrandt LW,. Perioperative immunomodulation in cancer surgery. Am J Surg. 1994; 167: 174-179.
36. Benish M, Bartal I, Goldfarb Y, et al., Perioperative use of β-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis. Ann Surg Oncol. 2008; 15: 2042-2052.
37. Greenfeld K, Avraham R, Benish M, et al., Immune suppression while awaiting surgery and following it: dissociations between plasma cytokine levels, their induced production, and NK cell cytotoxicity. Brain Behav Immun. 2007; 21: 503-513.
38. Bartal I, Melamed R, Greenfeld K, et al., Immune perturbations in patients along the perioperative period: alterations in cell surface markers and leukocyte subtypes before and after surgery. Brain Behav Immun. 2010; 24: 376-386.
39. Bar-Yosef S, Melamed R, Page GG, Shakhar G, Shakhar K, Ben-Eliyahu S,. Attenuation of the tumor-promoting effect of surgery by spinal blockade in rats. Anesthesiology. 2001; 94: 1066-1073.
40. Rosen CB, Nagorney DM, Taswell HF, et al., Perioperative blood transfusion and determinants of survival after liver resection for metastatic colorectal carcinoma. Ann Surg. 1992; 216: 493-504; discussion 504-495.
41. Law WL, Choi HK, Lee YM, Ho JW,. The impact of postoperative complications on long-term outcomes following curative resection for colorectal cancer. Ann Surg Oncol. 2007; 14: 2559-2566.